In patients with baseline HbA1c 53mmol/mol ( 7.0 % ) , 32.4 % of patients in the linagliptin group and 13.8 % in the placebo group achieved HbA1c < 53mmol/mol ( 7.0 % ) ( odds ratio2 .94 ; P = 0.0033 ) .